V-Key Announces Strategic Majority Investment in CloudsineAI to Advance AI Safety and Security for the AI Economy

SINGAPORE, Oct. 6, 2026 /PRNewswire/ -- V-Key, a Tower Capital Asia ("TCA") portfolio company and a leading provider of digital identity and Mobile Application Protection & Security ("MAPS"), today announced a strategic investment in Singapore-based CloudsineAI, a provider of AI cybersecurity and web integrity protection.

The investment advances V-Key's strategy to address the evolving safety, identity, and security requirements of the AI economy. By integrating V-Key's expertise in trusted digital identity and cryptographic protection with CloudsineAI's AI cybersecurity capabilities, already adopted by private and public sector organisations, the companies aim to provide trusted infrastructure for secure AI adoption and the next generation of digital interactions.

As organisations accelerate digital transformation and AI adoption, AI safety is becoming an increasingly important priority for governments and enterprises. Security must now extend beyond authenticating human users to securing applications, AI agents, and other non-human actors that initiate transactions and access systems.

V-Key and CloudsineAI bring together complementary strengths spanning trusted identity, agentic security, and governance. Together, they enable organisations to establish verifiable identities, safeguard digital interactions, and maintain accountability across critical business processes.

"This strategic investment reflects our conviction that identity will become the control layer for the AI economy," said Joseph Gan, Co-Founder and CEO of V-Key. "As organisations deploy AI agents alongside human users, AI safety requires more than authentication. Trusted identity, governed access, secure digital interactions, and verifiable accountability will be critical. By combining V-Key's expertise in identity management and application security with CloudsineAI's strengths in agentic cybersecurity, we are building the trust infrastructure for secure and responsible AI-powered services."

Matthias Chin, Founder and CEO of CloudsineAI, said, "Digital and AI transformation increasingly depends on trust between people, organisations, applications, and AI agents. Together with V-Key, we are combining identity governance with TraceCtrl's agentic AI security suite, giving customers greater identity, visibility, traceability, and control as they deploy AI."

The combined offering will provide customers across regulated industries, including financial services, government, healthcare, and critical infrastructure, with a more integrated approach to securing digital and AI interactions, strengthening governance, and supporting regulatory compliance.

Seth Lim, Senior Vice President at Tower Capital Asia, said, "Our investment in V-Key was founded on the belief that identity and digital trust will become foundational to the next generation of the digital economy. V-Key's strategic investment in CloudsineAI extends this vision into AI safety, combining its strengths in digital identity and application security with CloudsineAI's expertise in AI cybersecurity. We see significant opportunities for innovation and expansion across Asia-Pacific and beyond."

About V-Key

Founded in 2011, V‑Key provides digital identity, authentication, and mobile application security for banks, enterprises, and government‑linked organisations. Its AI-powered platform, built around the patented V‑OS Virtual Secure Element and V-OS App Identity, delivers hardware‑grade security in software, enabling secure onboarding, access and transaction protection across regulated digital markets in Asia and beyond.

www.v-key.com

About CloudsineAI

CloudsineAI is a Singapore-based provider of AI security and web integrity protection. Its proprietary platforms include TraceCtrl, an agentic AI security suite, and WebOrion^®, a web integrity protection platform trusted by enterprises and government customers in Singapore and four other countries.

www.cloudsine.tech

About Tower Capital Asia

Established in 2016, Tower Capital Asia is a mid-market private equity firm based in Singapore. The firm has led investments in the privatisation and/or buyout of Southeast Asian businesses including AXS, BoardRoom, Eu Yan Sang, and V-Key. As of 30 June 2026, the firm manages assets of more than US$900 million in investments and commitments across all vehicles.

www.towercapitalasia.com 

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

V-Key Announces Strategic Majority Investment in CloudsineAI to Advance AI Safety and Security for the AI Economy

Botanical oral-care product bridges 1974 Oregon State University discovery of 'oregonin' with 27 years of natural-product research by South Korean scientists.

SEOUL, South Korea, Oct. 6, 2026 /PRNewswire/ -- Dr. Oregonin Inc. today announced that it has completed U.S. Food and Drug Administration (FDA) registration for OLTIS DENTAL-X, paving the way for its official commercial entry into the North American oral-care market.

The product's authorization follows 27 years of research led by Professor Sun Eun Choi at Kangwon National University in South Korea, a specialist in pharmacognosy and natural products and recipient of Korea's Dongtap Order of Industrial Service Merit. Professor Choi's research team validated the biological efficacy and chemical profile of oregonin extracted from native Korean alder (Alnus japonica), securing Korean National New Excellent Technology (NET) Certification and regulatory clearance from South Korea's Ministry of Food and Drug Safety (MFDS).

The scientific history of the active compound traces directly back to the Pacific Northwest. In 1974, researchers at Oregon State University studying Red Alder (Alnus rubra) isolated a previously unknown polyphenolic diarylheptanoid xyloside and named it "oregonin" in honor of the state. Red Alder bark, roots, and leaves have a long history of traditional hygiene and medicinal use among indigenous and local communities in the Pacific Northwest, with modern phytochemical research confirming diarylheptanoids like oregonin as primary bioactive constituents.

Professor Choi's comparative research demonstrated that oregonin derived from Korean alder is chemically identical to the compound originally characterized in American Red Alder and exhibits identical biological activities. This botanical connection bridges American natural science history with advanced Korean forest-bio manufacturing.

"Oregonin creates a fascinating scientific bridge between Korea and the United States," said Professor Choi. "The compound was first characterized from America's Red Alder by researchers at Oregon State University. Decades later, our team translated this characteristic Alnus compound into an FDA-registered oral-care innovation. In that sense, this product has had an authentic connection to America from its inception."

Following its FDA registration, Dr. Oregonin Inc. is currently actively pursuing retail and distribution partnerships across major U.S. commercial channels to introduce OLTIS DENTAL-X to North American consumers.

About Dr. Oregonin Inc.

Dr. Oregonin Inc. is a South Korean forest-bio research and manufacturing company specializing in natural product development, pharmacognosy, and oral-care technology derived from sustainable forest resources.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Dr. Oregonin Completes U.S. FDA Registration for OLTIS DENTAL-X, Unveiling Oral-Care Innovation Rooted in Trans-Pacific Alder Research